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Long-term oxygen therapy is well established
as an important part of our therapeutic options for
severe COPD. However, for a therapy whose scien-
tific basis was established almost 30 years ago, it
is surprising that there is considerable turmoil in
the field. Some of this is the result of positive de-
velopments, some a result of remaining uncerta-
inly about our use of this therapy and some a re-
sult, seemingly, of inadequate attention to assuring
that oxygen therapy is delivered to our patients
optimally. I am reminded the title of the 1966
movie “The Good, the Bad and the Ugly” (a classic
tale of the American West, featuring an excellent
cast headed by a young Clint Eastwood) and will
use this as the theme of this examination of the
state of the art in long-term oxygen therapy.
The good
If we wish to see what is good in recent develop-
ments in long-term oxygen therapy (LTOT), we can
look to technologic developments that have expanded
treatment options. If we review the recommendations
of the 5th Oxygen Consensus Conference, held in Wa-
shington, DC almost 10 years ago, we can find the fol-
lowing recommendation concerning ambulatory oxy-
gen therapy: “Ambulatory oxygen equipment must be
able to be carried by most patients on their person
during activities of daily living. Ambulatory LTOT
equipment must weigh less than 10 pounds and pro-
vide at least the equivalent of 2 L/min of continuous
flow oxygen for 4 hours or more” [1].
At the time, this was an ambitious require-
ment. Yet, in recent years, we have seen the intro-
duction of options that make lightweight ambula-
tory supplies widely available.
— Small portable liquid oxygen units, weighing
as little as 1.6 kg that the patient can fill from
a liquid oxygen reservoir have been developed.
Liquid oxygen is the most compact form of
oxygen storage, generating roughly 840 liters
of gas for every liter of liquid oxygen.
— Lightweight small oxygen cylinders are incre-
asingly an option. Carbon fiber wrapped alu-
minum cylinders weigh less than standard
tanks and have higher filling pressures. Attrac-
tive configurations weigh in at about 1.6 kg,
including the oxygen regulator.
Another major development concerns how
oxygen is delivered to our patients. The cost of
transporting oxygen to the patient is a major frac-
tion of the cost of oxygen supply. The stationary
concentrator, that separates oxygen from nitrogen
in the atmosphere, effectively solves this problem
for stationary oxygen supplies. But, until recently,
ambulatory oxygen had to be delivered to the pa-
tient’s home by a truck. Three “non-delivery” mo-
dels for oxygen have been developed.
— An oxygen concentrator is configured to fill
a lightweight oxygen cylinder that can then be
used as an ambulatory source.
— A recently introduced device incorporates
a stationary oxygen concentrator capable of ge-
nerating liquid oxygen. This liquid oxygen can
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plemental oxygen at all. Yet it deserves to be stres-
sed that these benefits have been demonstrated to
accrue only in patients with severe resting hypo-
xemia. Why, then, do most guidelines (including
Medicare guidelines in the United States) call for
oxygen to be prescribed if PaO2 falls below 55 torr
during exercise or sleep, even in patients with higher
PaO2 at rest [4]? It deserves to be stressed there is
no clinical trials that demonstrate better survival
when patients with isolated exercise or nocturnal
hypoxemia receive supplemental oxygen.
It can be argued that at least four large-scale
long-term clinical trials with a survival outcome
need to be performed:
— stationary oxygen plus ambulatory oxygen vs.
stationary oxygen alone for patients who are
hypoxemic both at rest and during exercise;
— ambulatory oxygen vs. no oxygen for patients
who are normoxic at rest and desaturate with
exercise;
— nocturnal oxygen vs. no oxygen for patients
who are normoxic at rest and desaturate with
sleep;
— stationary oxygen plus ambulatory oxygen vs. no
oxygen for patients with mild hypoxemia at rest.
The need for such clinical trials was empha-
sized by a recently-published National Heart Lung
and Blood Institute workshop report [5]. In fact,
one of these trials (the last in the list above) is in
the planning stage. This despite this question ha-
ving previously been addressed by an excellent
Polish study [6]. (It can be argued that the Polish
study had too small a sample size to definitely ex-
clude a clinically significant benefit.) This study,
dubbed the long-term oxygen therapy trial (LOTT)
proposes to recruit approximately 3200 COPD pa-
tients whose resting oxygen saturation is in the
range of 89–93% (i.e., milder hypoxemia than in-
corporated in current guidelines) and randomize
them to either full-time oxygen (stationary plus
ambulatory) or no oxygen therapy. The duration
of the trial is designed so that the average observa-
tion period is approximately 3.5 years; it is powe-
red to determine survival differences between the
two groups and is scheduled to be completed by
2013. Special challenges of this study include as-
suring that participants assigned to the LTOT arm
actually utilize supplemental oxygen for a large
fraction of their day; special procedures to assess
and promote oxygen adherence are incorporated.
The ugly
The challenges we face in efficiently delive-
ring LTOT differ from country to country and re-
then be used to fill a small portable liquid
oxygen unit.
— At least five portable oxygen concentrators
have been introduced in the past couple of
years. These units are battery powered and
range in weight from roughly 1.8 to 8 kg. Units
range in their time between battery charges
and in the flow rate of oxygen they generate.
These units have been approved in some coun-
tries (and by some airline companies) for use
in air flight.
Finally, a related technological development
has assisted in enabling patients to more efficien-
tly gauge their oxygen saturation during activities
of daily living. Affordable, reasonably accurate
pulse oximeters are being used by patients to gauge
their oxygen saturations on an ongoing basis. Al-
though the potential exists for patients to overly
focus on their oxygen saturation, it seems highly
likely that there is a net benefit.
The bad
Stated succinctly, “The Bad” is that we have
unanswered questions that weaken the founda-
tions of clinical practice guidelines for LTOT. To
understand why this might be so, consider why we
prescribe LTOT. Is it to maintain arterial oxygen
partial pressure (or oxygen saturation) above a cer-
tain threshold? It is important to realize that our
thresholds for treatment are rather arbitrary, esta-
blished (in essence) by the designers of the trials
that demonstrated the value of oxygen therapy (see
below). Is it to improve symptoms? Certainly sup-
plemental oxygen improves dyspnea (in particu-
lar, dyspnea on exertion) and improves exercise
tolerance. But it can be argued that a therapy as
expensive as LTOT (it has an estimated cost in the
United States of $3 billion annually) would not be
prescribed if symptomatic relief was its only be-
nefit. No, LTOT is prescribed because it improves
long-term prognosis. Specifically, in patients with
severe resting hypoxemia, it substantially prolongs
life. Therapies with mortality benefits have a spe-
cial place in our therapeutic armamentarium; we
are unlikely to deny such therapies irrespective of
cost. This was demonstrated in two studies perfor-
med in the late 1970s, led by Drs. Thomas Petty
and David Flenley [2, 3]. These studies involved
a total of only about 300 COPD patients, selected as
having severe resting hypoxemia (arterial oxygen
partial pressure less that 55 torr) on two occasions.
Survival was markedly better at three years in pa-
tients averaging 19 hours of supplemental oxygen
than those averaging 12 hours of oxygen or no sup-
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gion to region. I will emphasize the United States
perspective and invite the reader to consider the
situation in his/her own country.
Recertification issues
Perhaps the most common situation in which
LTOT is first prescribed is when the patient expe-
riences a disease exacerbation and is hospitalized.
A level of hypoxemia consistent with LTOT pre-
scribing guidelines is detected and the patient is
sent home with oxygen supplies. Many of these
patients will, however, experience an improvement
in oxygenation as their exacerbation resolves and,
after a time, will no longer meet oxygen prescri-
bing guidelines. A recent Canadian study found
that re-evaluation two months after exacerbation
resulted in roughly 20% of patients being able to
discontinue oxygen [7]. My personal estimate is
that, in the United States, this is likely a low-end
estimate. An organized system of recertification
would doubtless result in substantial cost savings.
Oxygen conserver effectiveness
Oxygen conservers are devices that endeavor
to maintain desired levels of oxygenation while
using less oxygen than continuous flow oxygen.
This is enabled by delivering oxygen early in the
inhalation (when the oxygen bolus is most likely
to reach the gas exchange area) and turning it off
in periods when it would be wasted (late in inha-
lation and during the whole of expiration). There
are several dozen oxygen conservers being marke-
ted, with a range of pulse-dosing strategies. These
oxygen conservers have made possible the revolu-
tionary availability of light-weight yet long-lasting
oxygen supplies. Few have received extensive cli-
nical testing in the patients for whom they are in-
tended. Anecdotal evidence exists that, particular-
ly during exercise, oxygen conservers sometimes
do not provide adequate oxygen saturation. Spe-
cifically, the assumption that the conserver setting
delivers an equivalent saturation to that obtained
with continuous flow oxygen with the same liter/
/minute flow is hazardous.
Oxygen titration practices
Oxygen flow rates often need to be adjusted
from the resting prescription when the patients
either exercises or sleeps. Rules of thumb that flow
rates should be increased, say, by a liter/minute in
either situation are to be discouraged. Patients
should be tested and titrated during both exercise
and sleep employing the device the patient will be
using. Only in this way can adequate treatment be
reasonably assured.
Benefits of lightweight supplies
Until fairly recently, the standard provision of
ambulatory oxygen was by means of an E-cylinder
mounted on a cart and towed by the patient. This
configuration weighs about 10 kg and has been
perceived as being an impediment to ambulation.
Recently, as detailed above, lightweight oxygen
supplies have been introduced. Intuitively, light-
weight ambulatory supplies should engender
a range of benefits, including:
— promoting an increase in activities of daily living;
— increasing the number of hours the patient
uses supplemental oxygen;
— improving long-term outcomes.
However, we lack clinical studies convincin-
gly demonstrating any of these benefits.
Adherence to oxygen therapy
LTOT is expensive therapy. For patients with
severe hypoxemia, the long-term clinical trial evidence
we have, tells us that the more hours per day that oxy-
gen is used, the better the survival outcome. However,
the few studies that have estimated adherence have,
shown that adherence is not generally good [8, 9]. It
seems reasonable to propose that adherence monito-
ring and promotion should have high priority. I make
the specific suggestion that pulmonary rehabilitation
is a good setting for LTOT adherence promotion and
that, whenever possible, all LTOT patients should be
considered for pulmonary rehabilitation.
Governmental attempts
to reduce oxygen therapy costs
Budgetary constraints coupled with rising num-
bers of patients receiving LTOT have spurred regula-
tors to devise strategies to reduce LTOT costs. In the
United States, one proposal has been to, after an ini-
tial period, mandate that patients own and maintain
their oxygen equipment. Another proposal requires
that oxygen suppliers be selected regionally by a bid-
ding process awarding the lowest bidder exclusive
distribution rights. These specific proposals have re-
cently been tabled, but these and similar proposals are
likely to be pursued as cost cutting measures.
In conclusion, long-term oxygen therapy is
a valuable therapeutic option in a subset of late sta-
ge COPD patients. However, a substantial amount
of work remains before we can claim to be capable
of its optimal delivery.
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